A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)
Clinical trial NCT05526755 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05526755
- Sponsor
- AstraZeneca
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-06
- Primary completion
- 2029-11-22
- Enrollment
- 188
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.